Alerts will be sent to your verified email
Verify EmailLAURUSLABS
Laurus Labs
|
PI Industries
|
Glenmark Life Scienc
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
US DMF Filings
|
86.0 . | n/a | 532.0 . |
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in Europe
|
18.0 | n/a | n/a |
Number of ANDA's Approved in Europe
|
15.0 | n/a | n/a |
Number of ANDA's Filed in USA
|
41.0 . | n/a | n/a |
Number of ANDA's Approved By USFDA
|
35.0 . | n/a | n/a |
Number of ANDA's Approved by Canada
|
15.0 | n/a | n/a |
Number of ANDA's Filed in Canada
|
22.0 | n/a | n/a |
R&D as a % of Total Sales
|
5.4 % | n/a | 3.0 % |
Financials
|
|||
5 yr Average ROE
|
20.05 % | 16.28 % | 37.41 % |
5yr average Equity Multiplier
|
2.06 | 1.54 | 2.33 |
5yr Average Asset Turnover Ratio
|
0.74 | 0.62 | 0.76 |
5yr Avg Net Profit Margin
|
12.47 % | 17.3 % | 20.19 % |
Price to Book
|
6.17 | 8.12 | 6.25 |
P/E
|
171.05 | 40.55 | 32.6 |
5yr Avg Cash Conversion Cycle
|
109.81 Days | 6.11 Days | 76.63 Days |
Inventory Days
|
110.32 Days | 71.83 Days | 93.94 Days |
Days Receivable
|
117.42 Days | 38.9 Days | 125.3 Days |
Days Payable
|
143.67 Days | 99.98 Days | 114.87 Days |
5yr Average Interest Coverage Ratio
|
9.19 | 41.85 | 320.13 |
5yr Avg ROCE
|
24.17 % | 17.54 % | 51.63 % |
5yr Avg Operating Profit Margin
|
24.88 % | 25.35 % | 30.74 % |
5 yr average Debt to Equity
|
0.56 | 0.06 | 0.0 |
5yr CAGR Net Profit
|
-9.19 % | 29.79 % | 8.5 % |
5yr Average Return on Assets
|
9.61 % | 10.7 % | 15.32 % |
Shareholdings
|
|||
Promoter Holding
|
27.18 % | 46.09 % | 82.85 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 9.47 % |
Change in Promoter Holding (3 Yrs)
|
-0.12 % | -0.65 % | 0.01 % |
Change in Mutual Fund Holding (3 Yrs)
|
6.86 % | 1.96 % | 0.71 % |
Laurus Labs
|
PI Industries
|
Glenmark Life Scienc
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|